당뇨병성 망막병증 시장 : 시장 예측(2026-2032년)

The Diabetic Retinopathy Market is projected to grow by USD 14.87 billion at a CAGR of 6.41% by 2032.

Diabetic Retinopathy Executive Summary

Diabetic retinopathy is one of the most consequential microvascular complications of diabetes and a leading cause of preventable vision loss among working-age adults. The condition develops when prolonged hyperglycemia damages retinal blood vessels, progressing from non-proliferative diabetic retinopathy to proliferative diabetic retinopathy and, in many patients, diabetic macular edema. The clinical burden is rising in parallel with global diabetes prevalence, longer life expectancy, urbanized lifestyles, and uneven access to routine eye screening. International health authorities and ophthalmology guidelines consistently emphasize early detection because timely retinal imaging, glycemic control, blood pressure management, lipid control, laser therapy, intravitreal pharmacotherapy, and surgical intervention can reduce the risk of severe vision impairment.

The diabetic retinopathy landscape is increasingly shaped by integrated care pathways that connect endocrinology, ophthalmology, primary care, optometry, teleophthalmology, and digital health infrastructure. Healthcare systems are prioritizing scalable diabetic eye screening programs, referral optimization, and adherence-focused treatment models to address late diagnosis and follow-up gaps. As a result, industry stakeholders are focusing on evidence-based retinal imaging, artificial intelligence-enabled detection, anti-VEGF and corticosteroid-based therapeutic approaches, sustained-delivery technologies, and patient-centric monitoring models. The strongest opportunities are emerging where clinical need, reimbursement alignment, technology readiness, and screening accessibility intersect.

Transformative Shifts in the Diabetic Retinopathy Landscape

The diabetic retinopathy ecosystem is undergoing a structural shift from episodic specialist-led diagnosis toward continuous, risk-based retinal care. Traditional pathways often depended on patients reaching ophthalmology clinics after symptoms appeared, but diabetic retinopathy can remain asymptomatic until advanced stages. This has accelerated the adoption of routine retinal photography in primary care, pharmacy-linked health services, mobile screening units, diabetes clinics, and community health programs. The result is a broader movement toward earlier identification, faster triage, and more equitable access to eye care.

Therapeutic strategies are also evolving. Anti-VEGF injections remain central for diabetic macular edema and proliferative diabetic retinopathy management, while laser photocoagulation and vitrectomy continue to play important roles in selected cases. At the same time, sustained-release drug delivery, longer-acting biologics, combination regimens, and inflammation-targeting approaches are being evaluated to reduce treatment burden and improve durability. Patient adherence has become a major strategic focus because repeated clinic visits, injection anxiety, transportation barriers, and out-of-pocket costs can interrupt care.

Another transformative shift is the convergence of diabetes management and ophthalmic prevention. Clinicians are increasingly linking retinal outcomes to systemic control, including HbA1c, blood pressure, lipid management, kidney disease status, pregnancy, and duration of diabetes. This is changing how risk stratification is performed and how multidisciplinary teams intervene before irreversible retinal damage occurs. Digital workflows, image repositories, interoperable electronic health records, and remote specialist review are becoming essential tools in this transition.

Cumulative Impact of Artificial Intelligence on Diabetic Retinopathy Care

Artificial intelligence is having a cumulative impact on diabetic retinopathy by improving the scalability, consistency, and speed of retinal screening. AI-enabled image analysis can identify referable diabetic retinopathy from fundus photographs, support triage decisions, and reduce the burden on ophthalmologists in high-volume screening environments. Regulatory acceptance of autonomous and assistive AI systems in several healthcare settings has validated the clinical relevance of algorithm-based retinal assessment, provided that implementation follows rigorous quality assurance, cybersecurity, clinical governance, and equity standards.

The most immediate value of AI lies in expanding screening coverage, particularly in underserved areas where retina specialists are scarce. Automated grading can help primary care clinics, diabetes centers, and community screening programs identify patients who require urgent referral while allowing low-risk patients to remain in routine surveillance. AI can also support workflow prioritization, image quality assessment, and longitudinal tracking when integrated with electronic medical records and teleophthalmology networks.

However, the cumulative impact of artificial intelligence depends on more than algorithm accuracy. Performance must be validated across diverse populations, camera types, imaging protocols, disease severities, and comorbid ocular conditions. Bias mitigation is essential because diabetes prevalence, retinal pigmentation, cataract and media opacity, and healthcare access vary significantly across regions. Sustainable AI deployment also requires trained staff, clear referral pathways, reimbursement mechanisms, explainable outputs, and ongoing monitoring to prevent false reassurance or unnecessary referrals. When implemented responsibly, AI can become a major enabler of preventive retinal care rather than a replacement for specialist judgment.

Key Regional Insights Across Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific carries a substantial diabetic retinopathy burden due to the high number of people living with diabetes in China, India, Southeast Asia, Japan, South Korea, and Australia. Rapid urbanization, dietary transition, and aging populations are increasing the need for large-scale retinal screening, while access to ophthalmologists remains uneven between metropolitan and rural areas. Teleophthalmology, mobile retinal imaging, and AI-assisted screening are especially relevant across this region because they can extend diagnostic reach into primary care and community settings.

North America is characterized by advanced ophthalmic infrastructure, established diabetes care guidelines, broad use of retinal imaging, and growing integration of digital screening into primary care. The United States and Canada continue to emphasize routine dilated eye examinations or validated retinal imaging for people with diabetes, risk-based follow-up, and treatment adherence for diabetic macular edema and proliferative disease. Reimbursement structures, quality measures, and health system initiatives are supporting more systematic screening, although disparities persist among rural populations, Indigenous communities, uninsured groups, and patients facing transportation or cost barriers.

Latin America faces a dual challenge of rising diabetes prevalence and variable access to specialty eye care. Countries such as Brazil and Mexico have significant clinical need, with public health systems and private providers working to improve diabetic eye examination coverage. Urban centers have stronger ophthalmology capacity, while rural and lower-income communities often experience delayed diagnosis. Community-based screening, public-private clinical networks, and training of non-physician image capture personnel are becoming important strategies for improving timely detection.

Europe benefits from mature clinical guidelines, national screening programs in several countries, and strong emphasis on evidence-based ophthalmic care. The European landscape includes organized diabetic eye screening models, digital retinal image grading, and coordinated referral systems, particularly in countries with centralized health services. Differences remain across Western, Southern, Central, and Eastern Europe in screening coverage, treatment access, and adoption of advanced imaging. The region is also prominent in regulatory scrutiny around medical AI, data protection, interoperability, and clinical validation.

The Middle East is experiencing increasing diabetes-related eye disease due to high diabetes prevalence, sedentary lifestyles, and metabolic risk factors. Gulf countries are investing in specialty care, digital health infrastructure, and chronic disease management, while other parts of the region face workforce constraints and uneven access. Diabetic retinopathy programs in the Middle East increasingly focus on early detection, public awareness, and integration of retinal screening into diabetes clinics.

Africa has a growing diabetic retinopathy burden that is intensified by underdiagnosis of diabetes, limited access to routine eye examinations, shortages of ophthalmologists, and late presentation with advanced disease. Urban hospitals often manage severe cases, while rural communities may have minimal screening access. Scalable approaches such as mobile fundus photography, task-shifted screening, teleophthalmology, and AI-supported triage are highly relevant for improving prevention of avoidable blindness across the continent.

Key Group Insights Across ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are increasingly prioritizing diabetic retinopathy because diabetes prevalence has risen alongside urbanization, dietary changes, and aging populations. The region's diversity creates wide variation in eye care infrastructure, from advanced urban ophthalmology centers to rural settings with limited retinal specialists. Screening strategies that combine primary care, mobile imaging, teleophthalmology, and AI-enabled triage are especially important for Indonesia, Thailand, Malaysia, the Philippines, Vietnam, and neighboring countries where diabetes management programs are expanding.

The GCC shows strong strategic relevance because of high diabetes prevalence and substantial investment in healthcare modernization. Countries in the group are strengthening chronic disease programs, specialty eye care capacity, electronic health records, and digital health adoption. The diabetic retinopathy opportunity in the GCC is linked to integrating retinal screening into diabetes clinics, improving public awareness, reducing late-stage presentation, and using advanced imaging and AI tools to support high-throughput screening.

The European Union is defined by strong regulatory oversight, structured healthcare systems, and increasing adoption of organized diabetic eye screening pathways. EU priorities include clinical evidence, data privacy, interoperability, health technology assessment, and equitable access across member states. Diabetic retinopathy care in the European Union is moving toward standardized referral protocols, digital image grading, and outcome-focused management of diabetic macular edema and proliferative diabetic retinopathy.

BRICS countries represent a major share of the global diabetic retinopathy burden because they include large populations with rising diabetes prevalence, particularly China, India, Brazil, Russia, and South Africa. These healthcare systems face the challenge of scaling retinal screening across large geographies and mixed public-private delivery models. The group is highly relevant for teleophthalmology, cost-efficient imaging, workforce training, and AI-assisted detection because specialist distribution and rural access remain key constraints.

G7 countries generally have advanced ophthalmic services, established clinical guidelines, and strong research capabilities in retinal disease. The group is characterized by sophisticated imaging, anti-VEGF-based treatment pathways, digital health integration, and quality improvement initiatives focused on screening adherence. However, even in high-income systems, diabetic retinopathy outcomes are influenced by health inequities, aging populations, treatment burden, and differences in access among rural, low-income, and minority communities.

NATO countries span North America and Europe and include healthcare systems with varying levels of diabetic eye screening maturity. Many member countries have strong specialist networks, advanced diagnostic technologies, and growing interest in AI-enabled health infrastructure. For diabetic retinopathy, the group's relevance lies in interoperable digital health systems, clinical readiness for remote screening, resilient healthcare delivery, and prevention-focused chronic disease strategies that reduce avoidable vision loss.

Key Country Insights Across Major Diabetic Retinopathy Markets

The United States has a large diabetic retinopathy care ecosystem supported by clinical guidelines, retinal imaging infrastructure, intravitreal therapy access, and growing use of autonomous and assistive AI screening in primary care settings. The country's key challenge is not only clinical capability but also ensuring screening adherence among underserved, rural, uninsured, and minority populations. Canada emphasizes guideline-based diabetes eye care through a publicly funded healthcare environment, with attention to geographic access barriers affecting remote, rural, and Indigenous communities.

Mexico and Brazil face rising diabetes-related vision risk and uneven access to ophthalmology services. Mexico's burden is shaped by high diabetes prevalence, urban-rural disparities, and the need for broader preventive screening. Brazil has strong specialist capacity in major cities but faces access challenges across remote regions, making teleophthalmology, public screening initiatives, and referral coordination important. In the United Kingdom, organized diabetic eye screening is a defining feature, supported by systematic invitations, retinal photography, grading protocols, and referral pathways. Germany and France have advanced ophthalmic care systems with strong diagnostic and treatment capacity, although screening models are less centralized than in the United Kingdom and depend on coordinated outpatient care.

Russia presents a broad geographic access challenge, with specialist availability concentrated in larger cities and a need for improved chronic disease follow-up across dispersed populations. Italy and Spain have established ophthalmology networks and guideline-based care, with regional variations in screening organization and digital adoption. Both countries are increasingly focused on timely diabetic macular edema management, aging-related comorbidity, and improved coordination between diabetes specialists and eye care providers.

China has one of the world's largest populations living with diabetes, making scalable diabetic retinopathy screening a major public health priority. Urban hospitals have advanced retina services, while rural and lower-tier cities require more accessible imaging and referral systems. India similarly faces a substantial diabetic retinopathy burden, with early-onset type 2 diabetes, underdiagnosis, and uneven access driving demand for mobile screening, teleophthalmology, and AI-supported retinal assessment. Japan combines an aging population, strong ophthalmic expertise, and high-quality imaging infrastructure, with continued emphasis on long-term diabetes management and treatment adherence. Australia has advanced retinal care and national attention to diabetic eye disease, including the need to improve access for Aboriginal and Torres Strait Islander peoples and remote communities. South Korea benefits from digital health readiness, sophisticated ophthalmology services, and structured chronic disease management, making it well positioned for integrated screening and advanced retinal imaging workflows.

Actionable Recommendations for Diabetic Retinopathy Industry Leaders

Industry leaders should prioritize scalable diabetic retinopathy screening models that bring retinal imaging closer to patients with diabetes. Embedding fundus photography in primary care, endocrinology clinics, community health centers, pharmacies, and mobile programs can reduce missed screening opportunities. Organizations should align screening workflows with clear referral thresholds, fast-track pathways for sight-threatening diabetic retinopathy, and closed-loop follow-up systems that confirm whether patients reached specialist care.

Technology strategies should focus on clinically validated AI, interoperable imaging platforms, and data governance. AI tools should be evaluated across diverse patient populations and real-world imaging conditions before deployment. Leaders should establish continuous performance monitoring, image quality standards, staff training, cybersecurity controls, and physician oversight. Integration with electronic health records is essential for risk stratification, recall scheduling, and longitudinal disease tracking.

Therapeutic strategy should address treatment burden and adherence. Providers and innovators should support longer-acting therapies, sustained-delivery approaches, patient education, appointment navigation, and real-world evidence programs that identify reasons for missed visits. Multidisciplinary care models linking ophthalmologists, diabetologists, primary care physicians, pharmacists, nurses, optometrists, and community health workers can improve outcomes by connecting retinal disease management with systemic diabetes control.

Equity must remain central. Programs should target populations with lower screening rates, including rural communities, low-income patients, elderly individuals, Indigenous populations, migrant groups, and areas with limited specialist access. Public awareness campaigns should emphasize that diabetic retinopathy can progress without symptoms and that early detection can prevent vision loss. Industry stakeholders should also engage policymakers and payers to support reimbursement for screening, remote image interpretation, AI-assisted assessment, and care coordination.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified clinical, regulatory, epidemiological, and public health sources. The methodology emphasizes evidence from peer-reviewed ophthalmology and diabetes literature, international health agencies, clinical practice guidelines, regulatory communications, professional society recommendations, and national screening program documentation. Priority is given to sources that address diabetic retinopathy prevalence, disease progression, screening effectiveness, retinal imaging, artificial intelligence validation, diabetic macular edema treatment, and health system access barriers.

The analysis applies triangulation across multiple evidence streams to identify consistent industry signals without relying on market sizing, market share, or forecasting. Regional, group, and country insights are interpreted through factors such as diabetes burden, screening infrastructure, ophthalmologist availability, reimbursement environment, digital health readiness, guideline adoption, and equity of access. AI-related insights are assessed through clinical validation standards, real-world implementation considerations, and governance requirements.

The methodology avoids unsupported claims and excludes promotional positioning. It focuses on data-backed trends that are broadly substantiated by healthcare authorities, scientific publications, and established clinical practice patterns. Qualitative interpretation is used to connect epidemiological need with operational, technological, and therapeutic developments across diabetic retinopathy care pathways.

Conclusion

Diabetic retinopathy remains a major preventable cause of vision impairment, and its importance is intensifying as diabetes prevalence rises worldwide. The strongest strategic direction is clear: earlier screening, better referral coordination, sustained treatment adherence, and closer integration between retinal care and systemic diabetes management. Healthcare systems that shift from symptom-driven ophthalmology visits to proactive, image-based, risk-stratified screening will be better positioned to reduce avoidable blindness.

Artificial intelligence, teleophthalmology, mobile imaging, and interoperable digital health systems are reshaping the diabetic retinopathy landscape by making screening more scalable and accessible. Yet technology must be implemented with clinical validation, equity safeguards, and strong referral pathways to generate meaningful outcomes. Therapeutic innovation will continue to focus on durability, reduced treatment burden, and improved management of diabetic macular edema and proliferative diabetic retinopathy.

Across regions and countries, the central challenge is consistent: identifying patients early and keeping them connected to care. Industry leaders that combine evidence-based screening, responsible AI adoption, patient-centered treatment models, and equitable access strategies will play a critical role in preventing diabetes-related vision loss and strengthening the future of retinal healthcare.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Diabetic Retinopathy Market, by Product Type

• 7.1. Introduction
• 7.2. Anti-VEGF Agents
  • 7.2.1. Aflibercept
  • 7.2.2. Bevacizumab
  • 7.2.3. Ranibizumab
• 7.3. Corticosteroids
  • 7.3.1. Dexamethasone
  • 7.3.2. Triamcinolone
• 7.4. Laser Equipment
• 7.5. Surgical Implants

8. Diabetic Retinopathy Market, by Diabetic Type

• 8.1. Introduction
• 8.2. Non-Proliferative Diabetic Retinopathy
• 8.3. Proliferative Diabetic Retinopathy

9. Diabetic Retinopathy Market, by Patient Type

• 9.1. Introduction
• 9.2. Adult
• 9.3. Pediatric

10. Diabetic Retinopathy Market, by End-User

• 10.1. Introduction
• 10.2. Ambulatory Surgical Centers
• 10.3. Clinics
  • 10.3.1. General Clinics
  • 10.3.2. Specialty Clinics
• 10.4. Hospitals
  • 10.4.1. Private Hospitals
  • 10.4.2. Public Hospitals

11. Diabetic Retinopathy Market, by Region

• 11.1. Asia-Pacific
• 11.2. North America
• 11.3. Latin America
• 11.4. Europe
• 11.5. Middle East
• 11.6. Africa

12. Diabetic Retinopathy Market, by Group

• 12.1. ASEAN
• 12.2. GCC
• 12.3. European Union
• 12.4. BRICS
• 12.5. G7
• 12.6. NATO

13. Diabetic Retinopathy Market, by Country

• 13.1. United States
• 13.2. China
• 13.3. Germany
• 13.4. India
• 13.5. United Kingdom
• 13.6. Japan
• 13.7. France
• 13.8. Canada
• 13.9. Australia
• 13.10. Italy
• 13.11. Brazil
• 13.12. Russia
• 13.13. Mexico
• 13.14. Spain
• 13.15. South Korea

14. Competitive Landscape

• 14.1. Market Share Analysis, 2025
• 14.2. FPNV Positioning Matrix, 2025
• 14.3. Market Concentration Analysis, 2025
  • 14.3.1. Concentration Ratio (CR)
  • 14.3.2. Herfindahl Hirschman Index (HHI)
• 14.4. Recent Developments & Impact Analysis, 2025
• 14.5. Product Portfolio Analysis, 2025
• 14.6. Benchmarking Analysis, 2025

15. Company Profiles

• 15.1. AbbVie Inc.
• 15.2. AEYE Health
• 15.3. Amgen Inc.
• 15.4. ANI Pharmaceuticals, Inc.
• 15.5. Bausch + Lomb Corporation
• 15.6. Bayer AG
• 15.7. BCN Peptides, S.A.U.
• 15.8. Boehringer Ingelheim International GmbH
• 15.9. Clearside Biomedical, Inc.
• 15.10. Eli Lilly and Company
• 15.11. Eyenuk, Inc.
• 15.12. EyePoint Pharmaceuticals, Inc.
• 15.13. F. Hoffmann-La Roche AG
• 15.14. Kodiak Sciences Inc.
• 15.15. Novartis AG
• 15.16. Ocugen, Inc.
• 15.17. Ocular Therapeutix, Inc.
• 15.18. Ocuphire Pharma, Inc.
• 15.19. OcuTerra Therapeutics
• 15.20. Opthea Limited
• 15.21. Oxurion NV
• 15.22. Pfizer, Inc.
• 15.23. Regeneron Pharmaceuticals, Inc.
• 15.24. REGENXBIO Inc.
• 15.25. RetinaRisk
• 15.26. RETMARKER
• 15.27. Samsung Biologics Co., Ltd.